Navigation Links
Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
Date:4/26/2010

NATURE Study to Compare LT-NS001 vs. naproxen in Phase 2b Clinical Study

WALTHAM, Mass., April 26 /PRNewswire-USNewswire/ -- Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal (GI) safety of its investigational drug LT-NS001 (naproxen etemesil).  The study will compare the cumulative rate of gastric ulcers vs. Naprosyn® after 12 weeks of treatment.  LT-NS001 is the most advanced compound in Logical's portfolio of patented Bio-activatedTM Prodrugs, which are being developed to improve the GI safety and tolerability of non-steroidal anti-inflammatory drugs (NSAIDs).  

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the bloodstream, it is converted rapidly and completely to the well known NSAID, naproxen. Previously, LT-NS001 demonstrated a significant (79%) decrease in the incidence of gastric ulcers in subjects after just 7.5 days, as compared to Naprosyn®.  

"Following the success of our proof-of-concept study of LT-NS001 vs. naproxen, the opportunity to demonstrate that our Bio-activated™ prodrug may provide a considerable GI safety improvement over traditional naproxen in patients using NSAIDs chronically is quite compelling," said Peter A. Lankau, Chief Executive Officer of Logical Therapeutics.  "We believe the NATURE study will confirm the improved GI safety profile of LT-NS001 and will be predictive of the pivotal endpoints as defined by the FDA. It will bring us one step closer to fulfilling the unmet medical need for a single-entity NSAID with a significantly improved GI safety profile," said Lankau.  

About the NATURE Study

The NATURE (Naproxen etemesil for Arthritis Treatment and Ulcer Reduction Evaluation) study design is a double-blind, double-dummy, twelve-week study of LT-NS001 (naproxen etemesil) vs. Naprosyn® (naproxen) in patients aged 45 to 80 years with osteoarthritis of the knee requiring ongoing NSAID therapy.  The study is expected to complete enrollment in the fourth quarter of 2010 with 534 patients in the United States and United Kingdom.  Patients will be randomly assigned to either LT-NS001 or Naprosyn® and will undergo endoscopies at months one, two and three.  The primary endpoint is the cumulative incidence of subjects with gastric ulcers in each arm.

In addition to GI safety, injury and tolerability, the study will assess the efficacy of LT-NS001, through the use of the WOMAC functional score, stiffness score and total score for the index knee joint. This evaluation of osteoarthritis pain is designed to confirm the efficacy of LT-NS001, as compared to a therapeutically equivalent dose of naproxen during 12 weeks of B ID dosing, and may be particularly useful for prescribing physicians who are familiar with the use of naproxen.

About LT-NS001

LT-NS001 is the first in a new class of Bio-activated™ Prodrugs being developed for the treatment of chronic inflammatory conditions, such as osteoarthritis and rheumatoid arthritis.  Prodrugs are compounds that are inactive until enzymes in the body activate them.  Logical's NSAID prodrugs are unique because they are activated only when they reach the bloodstream.  Because they are not active in the gastrointestinal tract, they avoid GI injury and provide improved overall GI safety.

Despite the wide availability of gastro-protective agents such as proton pump inhibitors (PPI) or histamine-2 receptor antagonists (H2), serious NSAID-induced GI complications, including hemorrhage and perforation persist and are directly responsible for approximately 20,000 deaths in the U.S. each year.  Furthermore, the chronic administration of PPIs has been associated with serious side effects such as interference with anti-platelet treatments, increased susceptibility to infections and increased risk of bone fracture.  LT-NS001 utilizes a proprietary technology which has demonstrated improved GI safety without the need for concomitant alkalinizing agents and their associated risks.  

NSAIDs are among the most commonly used medications in the world.  Older age and the need for regular NSAID therapy increase the risk of NSAID-induced GI complications.   The use of NSAIDs is also associated with serious cardiovascular risks, including an increased risk of heart attacks and strokes.  LT-NS001 is converted by enzymes to naproxen, which is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

LT-NS001 is an investigational drug product candidate undergoing clinical evaluation and has not been approved by the U.S. Food and Drug Administration.

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biotechnology company focused on the development of Bio-activated Prodrugs to treat inflammatory conditions such as osteoarthritis and rheumatoid arthritis.  The Company's Bio-activated TechnologyTM has created a portfolio of molecules including LT-NS001, a naproxen prodrug and several additional Bio-activated NSAID pro-drug candidates, covered by issued and pending patents throughout the world.  Each program addresses unmet medical needs in multi-billion dollar markets.  For more information about Logical Therapeutics, visit the Company's website at www.logicaltx.com.

Please address inquiries regarding LT-NS001 to Logical Therapeutics' business development department at bd@logicaltx.com.

Bio-activated TechnologyTM is a trademark of Logical Therapeutics, Inc.


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
2. Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
3. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
4. Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
5. Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago
6. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
7. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
8. Reportlinker Adds Audiological Devices - Global Market Trends
9. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
10. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
11. Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... IL (PRWEB) , ... February 06, 2016 , ... ... recovery phases of eating disorder treatment helps to reduce the frequency and level ... of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... ... The American public tends to feel uncomfortable about drinking recycled waste water ... well water. The recent experience with lead contaminated water in Flint, Michigan, according to ... increasing public acceptance of recycled waste water as drinking water. , The Flint ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):